Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy

Jan H. Beumer; Edward Chu; Carmen Allegra; Yusuke Tanigawara; Gerard Milano; Robert Diasio; Tae Won Kim; Ron H. Mathijssen; Li Zhang; Dirk Arnold; Katsuki Muneoka; Narikazu Boku; Markus Joerger

doi:10.1002/cpt.1124

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy

Jan H. Beumer, Edward Chu, Carmen Allegra, Yusuke Tanigawara, Gerard Milano, Robert Diasio, Tae Won Kim, Ron H. Mathijssen, Li Zhang, Dirk Arnold, Katsuki Muneoka, Narikazu Boku, Markus Joerger

Research output: Contribution to journal › Review article › peer-review

74 Scopus citations

Abstract

5-Fluorouracil (5-FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.

Original language	English (US)
Pages (from-to)	598-613
Number of pages	16
Journal	Clinical Pharmacology and Therapeutics
Volume	105
Issue number	3
DOIs	https://doi.org/10.1002/cpt.1124
State	Published - Mar 2019
Externally published	Yes

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cpt.1124

Cite this

Beumer, J. H., Chu, E., Allegra, C., Tanigawara, Y., Milano, G., Diasio, R., Kim, T. W., Mathijssen, R. H., Zhang, L., Arnold, D., Muneoka, K., Boku, N., & Joerger, M. (2019). Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. Clinical Pharmacology and Therapeutics, 105(3), 598-613. https://doi.org/10.1002/cpt.1124

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. / Beumer, Jan H.; Chu, Edward; Allegra, Carmen et al.
In: Clinical Pharmacology and Therapeutics, Vol. 105, No. 3, 03.2019, p. 598-613.

Research output: Contribution to journal › Review article › peer-review

Beumer, JH, Chu, E, Allegra, C, Tanigawara, Y, Milano, G, Diasio, R, Kim, TW, Mathijssen, RH, Zhang, L, Arnold, D, Muneoka, K, Boku, N & Joerger, M 2019, 'Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy', Clinical Pharmacology and Therapeutics, vol. 105, no. 3, pp. 598-613. https://doi.org/10.1002/cpt.1124

@article{fa6ba5d101c84593ba764884918443c5,

title = "Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy",

abstract = "5-Fluorouracil (5-FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.",

author = "Beumer, {Jan H.} and Edward Chu and Carmen Allegra and Yusuke Tanigawara and Gerard Milano and Robert Diasio and Kim, {Tae Won} and Mathijssen, {Ron H.} and Li Zhang and Dirk Arnold and Katsuki Muneoka and Narikazu Boku and Markus Joerger",

note = "Publisher Copyright: {\textcopyright} 2018 American Society for Clinical Pharmacology and Therapeutics",

year = "2019",

month = mar,

doi = "10.1002/cpt.1124",

language = "English (US)",

volume = "105",

pages = "598--613",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Therapeutic Drug Monitoring in Oncology

T2 - International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy

AU - Beumer, Jan H.

AU - Chu, Edward

AU - Allegra, Carmen

AU - Tanigawara, Yusuke

AU - Milano, Gerard

AU - Diasio, Robert

AU - Kim, Tae Won

AU - Mathijssen, Ron H.

AU - Zhang, Li

AU - Arnold, Dirk

AU - Muneoka, Katsuki

AU - Boku, Narikazu

AU - Joerger, Markus

PY - 2019/3

Y1 - 2019/3

N2 - 5-Fluorouracil (5-FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.

AB - 5-Fluorouracil (5-FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.

UR - http://www.scopus.com/inward/record.url?scp=85053435195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053435195&partnerID=8YFLogxK

U2 - 10.1002/cpt.1124

DO - 10.1002/cpt.1124

M3 - Review article

C2 - 29923599

AN - SCOPUS:85053435195

SN - 0009-9236

VL - 105

SP - 598

EP - 613

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 3

ER -

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this